Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00580840 · ClinicalTrials.gov registry record · Phase 4
Dosing Flexibility Study in Patients With Rheumatoid Arthritis
A Phase 4 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 333
- Enrollment target
NCT00580840 is a Phase 4 study that has completed, run by UCB Pharma. The registered enrollment target is 333 participants.
The verdict
NCT00580840, a Phase 4 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 333 participants
- Enrollment target
Study Summary
During the run-in period, CZP will be administered at 400 mg (2 injections) at Wks 0, 2, and 4 and 200 mg with placebo (1 injection placebo, 1 injection CZP) at Wks 6, 8, 10, 12, 14 and 16. At Wk 18 patients will be grouped as responders or non-responders based on results of the ACR20 at Week 16.
Interventions
- OTHER Placebo
- DRUG Certolizumab pegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 333 participants |
| Start Date | 2007-12 |
| Est. Completion | 2011-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00580840
The ClinicalTrials.gov registry entry for NCT00580840 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 333 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00580840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00580840 about?
NCT00580840 is a clinical study titled "Dosing Flexibility Study in Patients With Rheumatoid Arthritis". During the run-in period, CZP will be administered at 400 mg (2 injections) at Wks 0, 2, and 4 and 200 mg with placebo (1 injection placebo, 1 injection CZP) at Wks 6, 8, 10, 12, 14 and 16. At Wk 18 patients will be grouped as responders or non-responders based on results of the ACR20 at Week 16.
What is the current status of trial NCT00580840?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 333 participants. The study started on 2007-12. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00580840?
The interventions under investigation include: Placebo (OTHER), Certolizumab pegol (DRUG).
Who is sponsoring clinical trial NCT00580840?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.